Modern Healthcare1d
Prior authorization reform falls short amid public frustrations
For patient advocates and health economists, cases like Ekirch’s illustrate why prior authorization has become such a chronic ...
Cigna, Aetna, Others Face Antitrust Claims Over Out-of-Network Payments
They are mistaken about the identity of Zelis’s clients, the operation of Zelis’s solutions, and the benefits Zelis provides ...
The Cigna Group (NYSE:CI) Receives $373.25 Average PT from Brokerages
The Cigna Group (NYSE:CI – Get Free Report) has been assigned a consensus rating of “Buy” from the seventeen research firms that are presently covering the firm, Ratings reports. Two research analysts ...
'They won’t help me': Sickest patients face insurance denials despite policy fixes
Ekirch said specialists have suggested that a series of infusions made from blood plasma called intravenous immunoglobulin -- ...
The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price
Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth. See why I rate CI stock a buy at current prices.
The Cigna Group (NYSE:CI) Upgraded at StockNews.com
StockNews.com upgraded shares of The Cigna Group (NYSE:CI – Free Report) from a buy rating to a strong-buy rating in a research note released on Saturday morning. CI has been the topic of several ...